<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00720512</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000598567</org_study_id>
    <secondary_id>GONO-BEBYP-ASL607LIOM03</secondary_id>
    <secondary_id>GONO-AIFA - FARM5C4FB4</secondary_id>
    <secondary_id>EUDRACT:2007-002886-11</secondary_id>
    <nct_id>NCT00720512</nct_id>
  </id_info>
  <brief_title>Second-Line Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer Who Have Received First-Line Chemotherapy and Bevacizumab</brief_title>
  <acronym>BEBYP</acronym>
  <official_title>AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE III STUDY OF SECOND-LINE CHEMOTHERAPY WITH OR WITHOUT BEVACIZUMAB IN METASTATIC COLORECTAL CANCER PATIENTS WHO HAVE RECEIVED FIRST-LINE CHEMOTHERAPY PLUS BEVACIZUMAB.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gruppo Oncologico del Nord-Ovest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gruppo Oncologico del Nord-Ovest</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as irinotecan, oxaliplatin, leucovorin, and&#xD;
      fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the&#xD;
      cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can&#xD;
      block tumor growth in different ways. Some block the ability of tumor cells to grow and&#xD;
      spread. Others find tumor cells and help kill them or carry tumor-killing substances to them.&#xD;
      It is not yet known whether combination chemotherapy is more effective with or without&#xD;
      bevacizumab in treating metastatic colorectal cancer.&#xD;
&#xD;
      PURPOSE: This randomized phase III trial is studying second-line combination chemotherapy to&#xD;
      see how well it works compared with or without bevacizumab in treating patients with&#xD;
      metastatic colorectal cancer who have received first-line chemotherapy and bevacizumab.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To compare the progression-free survival of second-line chemotherapy with or without&#xD;
           bevacizumab in patients with metastatic colorectal cancer who have received first-line&#xD;
           chemotherapy with bevacizumab.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To compare the overall survival, response rate, and safety profile of second-line&#xD;
           chemotherapy of these regimens in these patients.&#xD;
&#xD;
        -  To conduct pharmacogenomics assessment of candidate variants in the VEGF gene and&#xD;
           evaluate their association with progression-free survival and other study outcomes.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are stratified according to participating&#xD;
      center, ECOG performance status (0 vs 1-2), disease-free interval from the last&#xD;
      administration of first-line chemotherapy for metastatic disease (≤ 3 months vs &gt; 3 months),&#xD;
      and type of second-line chemotherapy (irinotecan hydrochloride, leucovorin calcium, and&#xD;
      fluorouracil [FOLFIRI] vs oxaliplatin, leucovorin calcium, and fluorouracil [mFOLFOX-6]).&#xD;
      Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive either irinotecan hydrochloride over 1 hour or oxaliplatin over&#xD;
           1 hour on day 1. Patients also receive leucovorin calcium IV over 2 hours and&#xD;
           fluorouracil IV over 46 hours continuously beginning on day 1.&#xD;
&#xD;
        -  Arm II: Patients receive combination chemotherapy as in arm I and bevacizumab IV on day&#xD;
           1.&#xD;
&#xD;
      Treatment in both arms repeats every 2 weeks for up to 12 courses in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      Existing formalin-fixed paraffin-embedded tumor tissue samples are assessed for&#xD;
      pharmacogenomics and markers predictive of response, resistance to, or toxicity from&#xD;
      bevacizumab. Samples are analyzed via RT-PCR, array comparative genomic hybridization,&#xD;
      fluorescence in situ hybridization, sequencing of candidate genes, and immunohistochemistry.&#xD;
&#xD;
      After completion of study treatment, patients are followed for 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>last progression of the last patient</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>the end of the stady</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>last visit of the last patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>the end of the study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">184</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive either irinotecan hydrochloride over 1 hour or oxaliplatin over 1 hour on day 1. Patients also receive leucovorin calcium IV over 2 hours and fluorouracil IV over 46 hours continuously beginning on day 1. Treatment repeats every 2 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive combination chemotherapy as in arm I and bevacizumab IV on day 1. Treatment repeats every 2 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed colorectal adenocarcinoma&#xD;
&#xD;
               -  Metastatic or unresectable disease&#xD;
&#xD;
          -  Progressive disease based on the following criteria:&#xD;
&#xD;
               -  Progression during or after first-line chemotherapy for metastatic disease,&#xD;
                  including any of the following:&#xD;
&#xD;
                    -  Fluoropyrimidine-based monotherapy with bevacizumab&#xD;
&#xD;
                    -  Fluoropyrimidine and irinotecan hydrochloride-based doublet with bevacizumab&#xD;
&#xD;
                    -  Fluoropyrimidine and oxaliplatin-based doublet with bevacizumab&#xD;
&#xD;
               -  Progression after more than 3 months from the last administration of first-line&#xD;
                  chemotherapy for metastatic disease with a fluoropyrimidine, irinotecan&#xD;
                  hydrochloride, and oxaliplatin triplet (FOLFOXIRI) with bevacizumab to which the&#xD;
                  patient had previously responded&#xD;
&#xD;
          -  Measurable disease, as assessed by RECIST criteria&#xD;
&#xD;
          -  No prior or concurrent CNS metastasis&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Life expectancy &gt; 3 months&#xD;
&#xD;
          -  ANC ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 9 g/dL&#xD;
&#xD;
          -  INR ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  aPTT ≤ 1.5 ULN&#xD;
&#xD;
          -  Serum bilirubin ≤ 1.5 times ULN&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 times ULN (&lt; 5 times ULN if liver metastases present)&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 2.5 times ULN (&lt; 5 times ULN if liver metastases present)&#xD;
&#xD;
          -  Serum creatinine ≤ 1.5 times ULN&#xD;
&#xD;
          -  Proteinuria &lt; 2+ OR protein ≤ 1g by 24-hour urine&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No bowel obstruction or subobstruction&#xD;
&#xD;
          -  No history of inflammatory enteropathy&#xD;
&#xD;
          -  No prior extensive intestinal resection (i.e., &gt; hemicolectomy or extensive small&#xD;
             intestine resection with chronic diarrhea)&#xD;
&#xD;
          -  No symptomatic peripheral neuropathy &gt; grade 2&#xD;
&#xD;
          -  No active uncontrolled infection&#xD;
&#xD;
          -  No active disseminated intravascular coagulation&#xD;
&#xD;
          -  No prior or concurrent malignancy, except for curatively treated basal cell and&#xD;
             squamous cell carcinoma of the skin, or in situ carcinoma of the cervix&#xD;
&#xD;
          -  No clinically significant cardiovascular disease, including any of the following:&#xD;
&#xD;
               -  Cerebrovascular accident within the past 6 months&#xD;
&#xD;
               -  Myocardial infarction within the past 6 months&#xD;
&#xD;
               -  Unstable angina&#xD;
&#xD;
               -  NYHA class II-IV chronic heart failure&#xD;
&#xD;
               -  Uncontrolled arrhythmia&#xD;
&#xD;
          -  No uncontrolled hypertension&#xD;
&#xD;
          -  No thromboembolic or hemorrhagic events within the past 6 months&#xD;
&#xD;
          -  No evidence of bleeding diathesis or coagulopathy&#xD;
&#xD;
          -  No serious, non healing wound/ulcer or serious bone fracture&#xD;
&#xD;
          -  No significant traumatic injury within the past 28 days&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 6 weeks since prior radiotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior surgery&#xD;
&#xD;
          -  No prior first-line chemotherapy for metastatic disease without bevacizumab&#xD;
&#xD;
          -  No prior cetuximab or other investigational agents&#xD;
&#xD;
          -  More than 28 days since prior open biopsy&#xD;
&#xD;
          -  More than 28 days since prior and no concurrent major surgical procedure&#xD;
&#xD;
          -  No concurrent therapeutic anticoagulation, antiplatelet agents, or NSAID with&#xD;
             anti-platelet activity&#xD;
&#xD;
               -  Acetylsalicylic acid ≤ 325 mg/day allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alfredo Falcone, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Presidio Ospedaliero di Livorno</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universita Politecnica Delle Marche</name>
      <address>
        <city>Ancona</city>
        <zip>60100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Usl 8 Arezzo</name>
      <address>
        <city>Arezzo</city>
        <zip>52100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale degli Infermi - ASL 12</name>
      <address>
        <city>Biella</city>
        <zip>13900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A. Perrino Hospital</name>
      <address>
        <city>Brindisi</city>
        <zip>72100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera S. Elia</name>
      <address>
        <city>Caltanissetta</city>
        <zip>93100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Santa Croce</name>
      <address>
        <city>Cuneo</city>
        <zip>12100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Giuseppe</name>
      <address>
        <city>Empoli</city>
        <zip>50053</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale E. Profili</name>
      <address>
        <city>Fabriano</city>
        <zip>60044</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile S. Croce</name>
      <address>
        <city>Fano</city>
        <zip>61032</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Firenze</name>
      <address>
        <city>Florence</city>
        <zip>50011</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Careggi</name>
      <address>
        <city>Florence</city>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale per la Ricerca sul Cancro</name>
      <address>
        <city>Genoa</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospendale S. Andrea EST</name>
      <address>
        <city>La Spezia</city>
        <zip>19100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Vito Fazzi</name>
      <address>
        <city>Lecce</city>
        <zip>73100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda USL12 Versilia</name>
      <address>
        <city>Lido di Camaiore</city>
        <zip>55043</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Campo Di Marte Lucca</name>
      <address>
        <city>Lucca</city>
        <zip>55100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Maggiore Della Carita</name>
      <address>
        <city>Novara</city>
        <zip>28100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Pisana</name>
      <address>
        <city>Pisa</city>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcispedale S. Maria Nuova</name>
      <address>
        <city>Reggio Emilia</city>
        <zip>42100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Senese</name>
      <address>
        <city>Siena</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento Oncologico</name>
      <address>
        <city>Siena</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>July 19, 2008</study_first_submitted>
  <study_first_submitted_qc>July 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2008</study_first_posted>
  <last_update_submitted>March 10, 2015</last_update_submitted>
  <last_update_submitted_qc>March 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 11, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma of the colon</keyword>
  <keyword>adenocarcinoma of the rectum</keyword>
  <keyword>recurrent colon cancer</keyword>
  <keyword>recurrent rectal cancer</keyword>
  <keyword>stage IV colon cancer</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <keyword>stage III rectal cancer</keyword>
  <keyword>stage III colon cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Calcium</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

